Annamaria Tomasso

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances
Published: October 22, 2025

Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.

Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.

Journal: Haematologica
Published: March 20, 2025

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.

Journal: Blood advances
Published: March 18, 2025

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience.

Journal: Hematological oncology
Published: December 02, 2024

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Journal: Hematological oncology
Published: November 15, 2024

Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia.

Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia.

Journal: Blood advances
Published: October 02, 2024

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.

Journal: HemaSphere
Published: May 28, 2024

Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature.

Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature.

Journal: Therapeutic advances in hematology
Published: May 27, 2024

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed.

Journal: Cancers
Published: April 16, 2024

What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.

What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.

Journal: Cancers
Published: December 13, 2023

Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience.

Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience.

Journal: Cancers
Published: October 19, 2023

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study.

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study.

Journal: Haematologica
Published: October 14, 2022
Showing 1-12 of 24

Last Updated: 09/26/2026